comscore Regeneron seeks FDA emergency clearance for COVID-19 therapy | Honolulu Star-Advertiser
Top News

Regeneron seeks FDA emergency clearance for COVID-19 therapy

  • DAVID MORRISON/ELI LILLY VIA ASSOCIATED PRESS
                                A researcher tested possible COVID-19 antibodies, in May, in a laboratory in Indianapolis. The drug company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study suggesting the drug reduced symptoms, the amount of virus and hospitalizations and ER visits for patients with mild or moderate COVID-19.

    DAVID MORRISON/ELI LILLY VIA ASSOCIATED PRESS

    A researcher tested possible COVID-19 antibodies, in May, in a laboratory in Indianapolis. The drug company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study suggesting the drug reduced symptoms, the amount of virus and hospitalizations and ER visits for patients with mild or moderate COVID-19.

Regeneron Pharmaceuticals Inc. said it has asked federal regulators to authorize its antibody treatment for Covid-19 for emergency use.

President Donald Trump received the antibody cocktail last Friday under a compassionate use program after becoming sick with the coronavirus. Trump hailed Regeneron’s treatment in a video posted on Twitter Wednesday, saying he would authorize its emergency use and make it available to Americans for free.

Regeneron shares gained 3.5% in late trading in New York after the Trump video was posted.

The experimental therapy is one of several monoclonal antibody treatments in testing that may help treat patients with Covid-19. Late last month, Regeneron reported preliminary results from a trial showing that the cocktail could reduce virus levels in coronavirus patients outside of the hospital.

In a statement, the company said that under its agreement with the U.S. government, if an emergency authorization is granted by the U.S. Food and Drug Administration, the government would make the initial doses available to the American people at no cost and would be responsible for their distribution.

Regeneron said it currently has doses available for approximately 50,000 patients, and expects to have doses available for 300,000 patients within the next few months.

Regeneron’s move follows Eli Lilly & Co., which said earlier Wednesday it is seeking emergency authorization for its Covid antibody treatment.

Click here to see our full coverage of the coronavirus outbreak. Submit your coronavirus news tip.

Be the first to know
Get web push notifications from Star-Advertiser when the next breaking story happens — it's FREE! You just need a supported web browser.
Subscribe for this feature
Comments (2)

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines.

Having trouble with comments? Learn more here.

Scroll Up